Table of Content
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Photopheresis Market
4. Market Overview
4.1. Introduction
4.1.1. By Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Key Market Indicators
4.3.1. Region/Country Specific
4.3.2. Product/Application/Therapeutic Area Specific
4.3.3. Target Market Specific – Global Scenario
4.4. Market Dynamics
4.4.1. Drivers
4.4.2. Restraints
4.4.3. Opportunity
4.4.Global Photopheresis Products Market Forecast, 2018-2027
4.4.1.Market Size Forecast
4.4.2.Pipeline Analysis
4.5.Organ and Stem Cell Transplantations Overview
4.6.Photopheresis Therapy Snapshot
4.7. Global Photopheresis Market Analysis and Forecasts, 2018-2027
4.7.1. Market Revenue Projections (US$ Mn)
4.8. Photopheresis Market - Global Supply Demand Scenario
4.9. Porter’s Five Force Analysis
4.10. Market Outlook
5. Global Photopheresis Market Analysis and Forecasts, By Product
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Key Trends
5.4. Market value Forecast By Product, 2018-2027
5.4.1. Open ECP system
5.4.2. Closed ECP system
5.5. By Product Comparison Matrix
5.6. Market Attractiveness By Product
6. Global Photopheresis Market Analysis and Forecasts, By End User
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Key Trends
6.4. Market value Forecast By End User, 2018-2027
6.4.1. Hospitals
6.4.2. Specialty Clinics
6.5. End User Comparison Matrix
6.6. Market Attractiveness By End User
7. Global Photopheresis Market Analysis and Forecasts, By Therapeutic Area
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Key Trends
7.4. Market value Forecast By Therapeutic Area, 2018-2027
7.4.1. Cutaneous T-cell Lymphoma
7.4.2. Graft-versus-Host Disease
7.4.3. Transplantation rejection
7.4.4. Autoimmune Disease
7.5. Therapeutic Area Comparison Matrix
7.6. Market Attractiveness By Therapeutic Area
8. Global Photopheresis Market Analysis and Forecasts, By Region
8.1. Key Findings
8.2. Policies and Regulations
8.3. Market value Forecast By Region
8.3.1. North America
8.3.2. Latin America
8.3.3. APAC
8.3.4. Europe
8.3.5. MEA
8.4. Market Attractiveness By Country/Region
9. North America Photopheresis Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.1.2. Policies and Regulations
9.1.3. Price Trend Analysis
9.1.4. Key Trends
9.2. Market value Forecast By Product, 2018-2027
9.2.1. Open ECP system
9.2.2. Closed ECP system
9.3. Market value Forecast By End User, 2018-2027
9.3.1. Hospitals
9.3.2. Specialty Clinics
9.4. Market value Forecast By Therapeutic Area, 2018-2027
9.4.1. Cutaneous T-cell Lymphoma
9.4.2. Graft-versus-Host Disease
9.4.3. Transplantation rejection
9.4.4. Autoimmune Disease
9.5. Market value Forecast By Country, 2018-2027
9.5.1. US
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Product
9.6.2. By End User
9.6.3. By Therapeutic Area
9.6.4. By Country
10. Latin America Photopheresis Market Analysis and Forecast
10.1.Introduction
10.1.1. Key Findings
10.1.2. Policies and Regulations
10.1.3. Price Trend Analysis
10.1.4. Key Trends
10.2.Market value Forecast By Product, 2018-2027
10.2.1. Open ECP system
10.2.2. Closed ECP system
10.3.Market value Forecast By End User, 2018-2027
10.3.1. Hospitals
10.3.2. Specialty Clinics
10.4.Market value Forecast By Therapeutic Area, 2018-2027
10.4.1. Cutaneous T-cell Lymphoma
10.4.2. Graft-versus-Host Disease
10.4.3. Transplantation rejection
10.4.4. Autoimmune Disease
10.5.Market value Forecast By Country, 2018-2027
10.5.1. Brazil
10.5.2. Mexico
10.5.3. Rest of Latin America
10.6.Market Attractiveness Analysis
10.6.1. By Product
10.6.2. By End User
10.6.3. By Therapeutic Area
10.6.4. By Country
11. APAC Photopheresis Market Analysis and Forecast
11.1.Introduction
11.1.1. Key Findings
11.1.2. Policies and Regulations
11.1.3. Price Trend Analysis
11.1.4. Key Trends
11.2.Market value Forecast By Product, 2018-2027
11.2.1. Open ECP system
11.2.2. Closed ECP system
11.3.Market value Forecast By End User, 2018-2027
11.3.1. Hospitals
11.3.2. Specialty Clinics
11.4.Market value Forecast By Therapeutic Area, 2018-2027
11.4.1. Cutaneous T-cell Lymphoma
11.4.2. Graft-versus-Host Disease
11.4.3. Transplantation rejection
11.4.4. Autoimmune Disease
11.5.Market value Forecast By Country, 2018-2027
11.5.1. Japan
11.5.2. India
11.5.3. China
11.5.4. Rest of APAC
11.6.Market Attractiveness Analysis
11.6.1. By Product
11.6.2. By End User
11.6.3. By Therapeutic Area
11.6.4. By Country
12. Europe Photopheresis Market Analysis and Forecast
12.1.Introduction
12.1.1. Key Findings
12.1.2. Policies and Regulations
12.1.3. Price Trend Analysis
12.1.4. Key Trends
12.2.Market value Forecast By Product, 2018-2027
12.2.1. Open ECP system
12.2.2. Closed ECP system
12.3.Market value Forecast By End User, 2018-2027
12.3.1. Hospitals
12.3.2. Specialty Clinics
12.4.Market value Forecast By Therapeutic Area, 2018-2027
12.4.1. Cutaneous T-cell Lymphoma
12.4.2. Graft-versus-Host Disease
12.4.3. Transplantation rejection
12.4.4. Autoimmune Disease
12.5.Market value Forecast By Country, 2018-2027
12.5.1. UK
12.5.2. France
12.5.3. Germany
12.5.4. Spain
12.5.5. Italy
12.5.6. Russia
12.5.7. Rest of Europe
12.6.Market Attractiveness Analysis
12.6.1. By Product
12.6.2. By End User
12.6.3. By Therapeutic Area
12.6.4. By Country
13. MEA Photopheresis Market Analysis and Forecast
13.1.Introduction
13.1.1. Key Findings
13.1.2. Policies and Regulations
13.1.3. Price Trend Analysis
13.1.4. Key Trends
13.2.Market value Forecast By Product, 2018-2027
13.2.1. Open ECP system
13.2.2. Closed ECP system
13.3.Market value Forecast By End User, 2018-2027
13.3.1. Hospitals
13.3.2. Specialty Clinics
13.4.Market value Forecast By Therapeutic Area, 2018-2027
13.4.1. Cutaneous T-cell Lymphoma
13.4.2. Graft-versus-Host Disease
13.4.3. Transplantation rejection
13.4.4. Autoimmune Disease
13.5.Market value Forecast By Country, 2018-2027
13.5.1. South Africa
13.5.2. Saudi Arabia
13.5.3. UAE
13.5.4. Rest of MEA
13.6.Market Attractiveness Analysis
13.6.1. By Product
13.6.2. By End User
13.6.3. By Therapeutic Area
13.6.4. By Country
14. Competition Landscape
14.1.Market Player – Competition Matrix (By Tier and Size of companies)
14.2.Market Share Analysis By Company (2019)
14.3.Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
14.3.1. Haemonetics Corporation
14.3.1.1.Company Overview
14.3.1.2.Financial Overview
14.3.1.3.Product Portfolio
14.3.1.4.Business Strategies
14.3.1.5.Recent Developments
14.3.2. Fresenius Kabi AG
14.3.2.1.Company Overview
14.3.2.2.Financial Overview
14.3.2.3.Product Portfolio
14.3.2.4.Business Strategies
14.3.2.5.Recent Developments
14.3.3. Macopharma
14.3.3.1.Company Overview
14.3.3.2.Financial Overview
14.3.3.3.Product Portfolio
14.3.3.4.Business Strategies
14.3.3.5.Recent Developments
14.3.4. Terumo Corporation
14.3.4.1.Company Overview
14.3.4.2.Financial Overview
14.3.4.3.Product Portfolio
14.3.4.4.Business Strategies
14.3.4.5.Recent Developments
14.3.5. Med Tech Solutions GmbH
14.3.5.1.Company Overview
14.3.5.2.Financial Overview
14.3.5.3.Product Portfolio
14.3.5.4.Business Strategies
14.3.5.5.Recent Developments
14.3.6. Mallinckrodt Pharmaceuticals
14.3.6.1.Company Overview
14.3.6.2.Financial Overview
14.3.6.3.Product Portfolio
14.3.6.4.Business Strategies
14.3.6.5.Recent Developments